A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Abroad (travel likely)RecruitingPHASE3

Conditions

Metastatic Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Illinois CancerCare PC, Peoria, Illinois, United States

  • Profound Research LLC at Cancer and Leukemia Center, Sterling Heights, Michigan, United States

  • Missouri Cancer Associates - 150518964, Columbia, Missouri, United States

  • SCRI Oncology Partners, Nashville, Tennessee, United States

  • Texas Oncology DFW, Bedford, Texas, United States

  • Texas Oncology- San Antonio, San Antonio, Texas, United States

  • GenesisCare North Shore (Oncology), St Leonards, New South Wales, Australia

  • Icon Cancer Centre Chermside, Chermside, Queensland, Australia

Study leads
  • Medical Responsible

    Study Director

    EMD Serono Research & Development Institute, Inc.